mekinist
novartis europharm limited - trametinib - melanomul - agenți antineoplazici - melanomatrametinib as monotherapy or in combination with dabrafenib is indicated for the treatment of adult patients with unresectable or metastatic melanoma with a braf v600 mutation (see sections 4. 4 și 5. trametinib monotherapy has not demonstrated clinical activity in patients who have progressed on a prior braf inhibitor therapy (see section 5. adjuvant treatment of melanomatrametinib in combination with dabrafenib is indicated for the adjuvant treatment of adult patients with stage iii melanoma with a braf v600 mutation, following complete resection. non-cancer pulmonar cu celule mici (nsclc)trametinib în combinație cu dabrafenib este indicat pentru tratamentul pacienților adulți cu avansate non-cancer pulmonar cu celule mici, cu o mutație braf v600.
mekinist 0,5 mg
glaxo wellcome, s.a. - spania - trametinibum - compr. film. - 0,5mg - inhibitori de protein-kinaza
mekinist 2 mg
glaxo wellcome, s.a. - spania - trametinibum - compr. film. - 2mg - inhibitori de protein-kinaza
spexotras 0,05 mg/ml
sandoz s.r.l. - romania - trametinibum - pulb. pt. sol. orala - 0,05mg/ml - inhibitori de protein-kinaza inhibitori ai proteinei kinazei activate de mitogen (mek)